BioSpace News Archive

Intensity Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Foundation Medicine Inc., announced that it has received approval from the U.S. Food and Drug Administration for FoundationOne®CDx to be used as a companion diagnostic for Janssen Biotech, Inc. AKEEGA™, which was approved by the FDA for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

2seventy bio, Inc today reported financial results and recent highlights for the second quarter ended June 30, 2023.

Kura Oncology, Inc. today announced the appointment of Brian Powl as Chief Commercial Officer.

Gracell Biotechnologies Inc. today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.

PDS Biotechnology Corporation will discuss its financial results for the quarter ended June 30, 2023 and provide a business update on its conference call today.

CNS Pharmaceuticals, Inc. today reported its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones.

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business update.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update.